ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2013
Reducing the burden of bone metastases: current concepts and treatment options.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature.Global journal of health science · 2015Pooled it
- Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Zoledronic acid in metastatic castrate-sensitive prostate cancer: A state-of-the-art review.Journal of bone oncology · 2025Review
- Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG).Journal of cancer research and clinical oncology · 2020Review
- Systematic review: Incidence, risk factors, survival and treatment of bone metastases from colorectal cancer.Journal of bone oncology · 2018Review
- Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway.Oncology letters · 2018Article
- Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom.BMC health services research · 2018Article
- Magnetic Resonance-Guided High-Intensity-Focused Ultrasound for Palliation of Painful Skeletal Metastases: A Pilot Study.Technology in cancer research & treatment · 2017Article
- The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey.European journal of cancer care · 2017Observational
- Intramedullary nailing has sufficient durability for metastatic femoral fractures.World journal of surgical oncology · 2016Article
- Targeting bone metastases in prostate cancer: improving clinical outcome.Nature reviews. Urology · 2015Review
- NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use.Cancer research · 2014Article
- Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Article
- Evaluating factors affecting length of hospital stay in patients with metastatic bone tumors.Journal of orthopaedicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone metastases occur frequently in patients with solid tumours such as those of the prostate, breast and lung, and are associated with an increased risk of skeletal-related events (SREs). This article reviews the personal, social and economic burdens of bone metastases and SREs, and approaches to treatment.
methodsPubMed searches were conducted using a broad range of search terms. Articles identified were refined by author review of abstracts. Additional material was identified by searching recent relevant congress abstracts.
resultsBone metastases often decrease quality of life, but quantitative data on the extent of this effect are limited. Data from the USA demonstrate a significant financial burden associated with bone metastases; similar trends are now being uncovered in Europe as the number of assessments of health economics and healthcare resource utilisation in the region increases. The bisphosphonate zoledronic acid reduces the incidence of SREs compared with placebo. Recent phase 3 studies have shown that therapy with the RANK ligand inhibitor denosumab is superior to zoledronic acid for preventing or delaying SREs in patients with bone metastases from solid tumours. Denosumab also has a comparable safety profile to bisphosphonates, with reduced risk of renal toxicity and acute phase reactions. Data from Europe suggest that denosumab is cost-effective for the prevention of SREs compared with zoledronic acid. Additionally, several new experimental bone-targeted agents show promise.
conclusionRecent progress may help to reshape evidence-based guidelines to improve patient care and reduce the economic burden of bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.